Garcia Laura de Castro E, Petry Lucas Montiel, Germani Pedro Augusto Van Der Sand, Xavier Luiza Fernandes, de Barros Paula Barros, Meneses Amanda da Silva, Prestes Laura Menestrino, Bittencourt Luana Braga, Pieta Marina Puerari, Friedrich Frederico, Pinto Leonardo Araújo
Centro Infant, Department of Pediatrics, School of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil.
Front Pediatr. 2022 May 16;10:881470. doi: 10.3389/fped.2022.881470. eCollection 2022.
Cystic fibrosis is the most common life-limiting recessive genetic disorder in Caucasian populations, characterized by the involvement of exocrine glands, causing multisystemic comorbidities. Since the first descriptions of pancreatic and pulmonary involvement in children, technological development and basic science research have allowed great advances in the diagnosis and treatment of cystic fibrosis. The great search for treatments that acted at the genetic level, despite not having found a cure for this disease, culminated in the creation of CFTR modulators, highly effective medications for certain groups of patients. However, there are still many obstacles behind the treatment of the disease to be discussed, given the wide variety of mutations and phenotypes involved and the difficulty of access that permeate these new therapies around the world.
囊性纤维化是白种人群中最常见的危及生命的隐性遗传病,其特征是外分泌腺受累,导致多系统合并症。自从首次描述儿童胰腺和肺部受累以来,技术发展和基础科学研究已使囊性纤维化的诊断和治疗取得了巨大进展。尽管尚未找到治愈这种疾病的方法,但对在基因水平起作用的治疗方法的大量探索最终促成了CFTR调节剂的问世,这是对某些患者群体非常有效的药物。然而,鉴于所涉及的突变和表型种类繁多,以及在世界各地普及这些新疗法存在困难,该疾病的治疗仍有许多障碍有待探讨。